Thursday, June 10, 2021

#ASCO21 Cancer Disparity Sessions

The theme for this year's ASCO annual meeting was EQUITY: EVERY PATIENT EVERY DAY EVERYWHERE.  I attended a number of sessions including  Equality in Care for All Women: Addressing Disparities in Gynecologic Malignancies and Social Determinants, Not Biology: Time to Reappraise Genetics- Based Theories of Racial/Ethnic Cancer Outcome Disparities and More Than the Patient: Structural Racism and Cancer Disparities.

Here are the tweets I posted during the sessions. 

Equality in Care for All Women: Addressing Disparities in Gynecologic Malignancies

Opening Session


Social Determinants, Not Biology: Time to Reappraise Genetics-Based Theories of Racial/Ethnic Cancer Outcome Disparities 


More Than the Patient: Structural Racism and Cancer Disparities


There are so many areas where we all can improve the care for "every patient everywhere" and these open  and honest discussions can make these needed changes happen.  



Every Day is a Blessing! 

Tuesday, June 8, 2021

ASCO 2021 Oral Abstract Session - GYN Cancers

I'll begin my coverage of the #ASCO21 Annual  meeting I have been attending virtually with comments and tweets from the Monday June 7th Gyneocologic Cancer Oral Abstract session. 


Not all the studies report were "blockbuster", not all provided results the researchers expected but in each and every one of them we - researchers, clinicians and patients learned something. 

 Here is my tweet summary:  


PDL1 inhibitor / Neoadjuvant chemo plus Bevacizumab

GEM vaccine  (Gemogenovatucel)

Bevacizumab 15 months vs 30 months 

Agent given to highlight tumors with overexpression of folate receptor Alpha during surgery

Mirvetuximab plus Bev for recurrent OC

Adavosertib w and w/out Olaparib

Endometrial Cancer 

Intensive Follow-up after endometrial cancer treatment

mTOR inhibitor and Anastrozole 

Pertuzumab and Trastuzumab in uterine cancer patients with ERBB2/ERBB3 


Over the next few days I'll be sharing tweets from the disparity, plenary ( cervical cancer study)  and poster sessions. Stay tuned. 


Every Day is a Blessing!

Wednesday, June 2, 2021

#ASCO21 Begins Soon

 The ASCO Annual meeting runs from June 7, 2021 to June 8, 2021. I am happy to once again attend this meeting which shares cancer research from across the globe. I wish it was in person but once more we will be meeting virtually. 


Here is a list of the sessions that relate to Gynecologic Cancer that I hope to attend.

I have also made a list of a  few abstracts of research that I would like to learn more about so I don't miss out on the discussion during the meetings sessions or online. 


5502 Oral Abstract Session

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial. Abstract 5502   (Vigil, an autologous tumor cell vaccine transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin for TGFβ expression control, following frontline platinum-based chemotherapy)


5501 Oral Abstract Session

Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). (BEV treatment duration of 15 months remains standard of care vs 30 months)



Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis  5504

The combination of MIRV with BEV demonstrates impressive anti-tumor activity with durable responses and favorable tolerability in high FRα recurrent ovarian cancer.

5503 Oral Abstract Session

Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. intraoperative near-infrared fluores- cence (NIRF) imaging with pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery. 

5506 Oral Abstract Session

Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708). Intensive follow-up in endometrial cancer treated patients showed a weak and uncertain advantage in detecting earlier asymptomatic relapses but did not improve OS, even in HiR patients, nor influenced HRQL.


5513 Poster Discussion Session 

Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. RAD51-deficient EOC have im- proved outcome after neoadjuvant platinum. Conversely, the RAD51 assay also identified a small subset of RAD51-high BRCAmut tumors with poor platinum response. Whether this RAD51 functional assay may also predict PARP inhibitor benefit is currently 


5519 Poster Discussion Session

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low- grade serous ovarian cancer (LGSOC). higher response rates and longer PFS were seen in those patients with LGSOC treated with binimetinib who harbored MAPK mutations, most commonly in KRAS. Somatic tu- mor testing should be routinely performed in patients with recurrent LGSOC to aid in clinical decision making.

5521 Poster Discussion Session

Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial. DCVAC improved PFS and OS outcomes in patients with newly diag- nosed EOC, predominantly in patients with immunologically “cold” tumors, 


5544 Poster Session

Nanoanalysis of plasma volatile organic compounds using novel DNA-decorated carbon nanotube vapor sensors to noninvasively distinguish ovarian and pancreatic cancer from benign and control samples. Prescreening test diagnostic approach based on vapor detection of ovarian and pancreatic cancer is achievable.

5548 Poster Session

Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas. ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy 

5553 Poster Session

Next generation sequencing in ovarian cancer patients: Does personalized medicine improve oncological outcomes? Our study suggests an OS benefit among the NGS tested cohort. We identified Loss of heterozygosity as a prognostic biomarker


5552 Poster Session- Disparities

Disparities in ovarian cancer treatment and overall survival according to race: An update. Overall survival remains worse for black patients, regardless of whether their care adhered to NCCN guidelines as defined by our study. This suggests that while receipt of care that is not adherent to NCCN guidelines seems to be negatively associated with overall survival, 

5571 Poster Session- Disparities

Race-related disparities in patterns of uterine cancer recurrence. non-White race is potentially contributory to distant recurrence of uterine can- cer, even when accounting for histopathologic differences, stage at presentation, and other traditional covariates.

Have you looked at the abstracts? Did some catch your eye? Please let me know and tag me ( @womenofteal in a tweet). Please be sure to use #gyncsm when you are tweeting from  the meeting too. 

I'll catch you all up on what I have learned with a few posts about this year's meeting. Stay tuned!


Every Day is a Blessing!